NVO News

Novo Nordisk A/S - share repurchase programme

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Planisware unveils latest AI innovations at its annual Exchange26 EMEA conference

Parker Waichman LLP Files Lawsuit on behalf of Massachusetts Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Wegovy

Novo Nordisk A/S - share repurchase programme

Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

The Brain & Behavior Research Foundation Presents: Neural Circuits Controlling Food-Seeking

Genomics Launches the Mystra AI Platform, Adopted by Industry Giants and Up-and-Coming Biotechs